RxDoctor Payments Data

Frank Oppong Takyi, MD

Internal Medicine · Phoenix, AZNPI 1497770465

Payments from drug & device makers

$1,677in general payments, 2019–2025

Across 57 payments — averaging $29.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$594
  • AstraZeneca$543
  • Boehringer Ingelheim$205
  • Lilly USA, LLC$67
  • Abbott$59
  • Optos, Inc.$49
  • plus $159 from 6 others

What the payments were for

  • Food & beverage$1,66299%
  • Entertainment$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,677 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$102,357
Medicare patients
188
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$104,741
OzempicSemaglutide37$39,844
JardianceEmpagliflozin31$38,268
FarxigaDapagliflozin Propanediol32$35,031
Atorvastatin Calcium396$3,250
SynthroidLevothyroxine Sodium26$3,214
Losartan Potassium297$3,134
Albuterol Sulfate HfaAlbuterol Sulfate90$1,967
Rosuvastatin Calcium106$1,913
Metoprolol Succinate132$1,865
Levothyroxine Sodium168$1,426
Amlodipine Besylate271$1,256
Metformin Hcl141$1,225
Gabapentin74$1,224
Potassium Chloride58$1,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$67$104,74182 claims
Novo NordiskOzempic$594$39,84437 claims
Boehringer IngelheimJardiance$205$38,26831 claims
AstraZenecaFarxiga$543$35,03132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →